Clinical Trials
27 trialsNew and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study
M.D. Anderson Cancer Center
Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
Inova Health Care Services
Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis
Wake Forest University Health Sciences
SMMART Adaptive Clinical Treatment (ACT) Trial
OHSU Knight Cancer Institute
Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma
M.D. Anderson Cancer Center
Selinexor Combination Ph 1 Study
Hackensack Meridian Health
Venetoclax and Irinotecan in Relapsed/Refractory SCLC
Virginia Commonwealth University
Surgery With Implantable Biodegradable Carmustine (BCNU) Wafer Followed by Chemo for Patients With Recurrent Glioblastoma Multiforme
University of Cincinnati
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
Washington University School of Medicine
FOLFOXIRI Chemotherapy Alone as Neoadjuvant Treatment for Circumferential Radial Margin (CRM) Positive Rectal Cancer
Guangxi Medical University
Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver
Memorial Sloan Kettering Cancer Center
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
New Mexico Cancer Research Alliance
Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer
Weill Medical College of Cornell University
Irinotecan Hydrochloride With FOLFIRI and Cetuximab as First-Line Therapy in Treating Patients With RAS Wild-Type Colorectal Cancer
University of Chicago
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Previously Untreated Metastatic Pancreatic Cancer
Alliance for Clinical Trials in Oncology
Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
Roswell Park Cancer Institute
Chemoembolisation With CPT11 Loaded DC Bead With Cetuximab and 5FU/LV in First Line in Patients With KRAS Wildtype mCRC
Universitaire Ziekenhuizen KU Leuven
A Pilot Study of Irinotecan in Patients With Breast Cancer and CNS Metastases
University of California, Irvine
Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
City of Hope Medical Center
Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
City of Hope Medical Center
A Protocol of Irinotecan for Carcinoma of the Lung
University of Kentucky
Crossover Evaluation of Effect of Atorvastatin on PK of Irinotecan in CRC Patients Receiving FOLFIRI
UNC Lineberger Comprehensive Cancer Center
IXO+A in mCRC With Liver-only Metastases
Ottawa Hospital Research Institute
Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
M.D. Anderson Cancer Center
Phase I/II Study of Paclitaxel Plus CPT-11 in Pts. With 2nd Line Chemotherapy of Inoperable or Recurrent GC.
Hokkaido Gastrointestinal Cancer Study Group